Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Vetigenics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Vetigenics

Vetigenics

Pre-Seed

Vetigenics develops innovative antibody therapies for cancer and chronic diseases in pets.

HQ
Philadelphia, PA, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

Vetigenics, founded in 2018, is dedicated to revolutionizing veterinary medicine by developing innovative antibody therapies for cancer and chronic diseases in pets. The company's core mission is to enhance the quality of life for companion animals through advanced, targeted immunotherapies. Vetigenics focuses on creating monoclonal antibodies that specifically target and treat various ailments in pets, with a particular emphasis on oncology and chronic conditions.

Notable affiliated individuals include experts in veterinary medicine and biotechnology, who bring extensive experience to the company. Vetigenics has garnered attention for its pioneering work, including the commencement of a pilot clinical trial for a canine anti-cPD1 monoclonal antibody aimed at treating bladder cancer in dogs. This milestone underscores the company's impact on advancing pet healthcare and its potential to transform treatment paradigms for chronic and life-threatening diseases in companion animals.

Vetigenics - Similar Companies

Curelab Veterinary logo

Curelab Veterinary

VetDC logo

VetDC

Vetmab Biosciences logo

Vetmab Biosciences

Animal Life Sciences logo

Animal Life Sciences

Gallant Pet logo

Gallant Pet

gallant.com

Ingenia Therapeutics logo

Ingenia Therapeutics

ingeniatx.com

PetDx logo

PetDx

MBF Therapeutics logo

MBF Therapeutics

Elias Animal Health logo

Elias Animal Health

Vetherapy logo

Vetherapy

FidoCure® logo

FidoCure®

fidocure.com

Invetx logo

Invetx

invetx.com

WayPath Pharma logo

WayPath Pharma

waypathpharma.com

Veterinary Prime logo

Veterinary Prime

Embark Veterinary logo

Embark Veterinary

embarkvet.com

Vetigenics - Quick Facts

Who are Vetigenics' competitors?

Companies similar to Vetigenics include Curelab Veterinary, VetDC, Vetmab Biosciences and Animal Life Sciences.

When was Vetigenics founded?

Vetigenics was founded in 2017.

Where is Vetigenics' headquarters located?

Vetigenics' headquarters is located in Philadelphia, PA, US.

When was Vetigenics' last funding round?

Vetigenics' most recent funding round was for $250k (USD) in February 2021.

How much has Vetigenics raised to-date?

As of Feb 7, 2021, Vetigenics has raised a total of $550k (USD).

How many employees does Vetigenics have?

Vetigenics has 9 employees as of Feb 4, 2024.

Vetigenics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Antibody Therapies
Tags
  • Biotech
  • Healthtech